George Kumar, Senior Director of Medical Diagnostics, Pan Tumor and GI Cancers at AstraZeneca, shared a post on LinkedIn:
“A nice review of “ The immunology of brain tumors”
Brain tumors remain one of the toughest frontiers for immunotherapy. While metastatic brain tumors show higher immunogenicity and better responses, primary brain tumors are shaped by a highly suppressive microenvironment. Advancing vaccines, checkpoint inhibitors, and adoptive T-cell therapies – combined with deeper knowledge of tumor antigenicity – will be critical for unlocking more effective treatment strategies.
Figure Courtesy: Science Immunology and Michael Platten : Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Development of brain metastases and gliomas and Routes of T cell priming to brain tumor–derived antigens.”
Brain Tumor Chemotherapy Success Rate: What Patients Need to Know in 2025
